Vaccine Researcher to Speak April 27

Larry Grill of Claremont’s Keck Graduate Institute will discuss the next generation of vaccines, biologic pharmaceuticals

Larry Grill

Vaccine researcher Larry Grill will discuss the next generation of vaccines and biologic pharmaceuticals on April 27.

RIVERSIDE, Calif. – Vaccine researcher Larry Grill, dean of research at the Keck Graduate Institute in Claremont, will discuss “The Next Generation of Vaccines and Biologic Pharmaceuticals” at the University of California, Riverside on Monday, April 27, at 4 p.m. in the School of Medicine Education Building, G650.

Grill’s presentation is free and open to the public. Parking permits may be obtained at the kiosk on West Campus Drive near the University Avenue entrance to the campus.

Reservations are requested and may be made online or by emailing The lecture is sponsored by the University of California Global Health Institute’s One Health Center, which is based at UCR, the School of Medicine and the School of Public Policy.

Grill, who earned his Ph.D. at UCR, also is the director of the Vaccine Research Center, which has research laboratories at the Keck Graduate Institute (KGI) and Pitzer College. He also teaches courses at the Claremont Colleges Keck Science Department and at KGI.

Since 2009, students working at the Vaccine Research Center have been involved in research projects to develop low-cost vaccines for economically important diseases in Africa, collaborating with researchers at the University of Botswana and the Botswana Vaccine Institute, among others.

Before joining the Claremont Colleges, Grill was a founder of Large Scale Biology Corp. (LSBC), which became a publicly held company in 2000. The biotechnology company made therapeutic drugs, pharmaceuticals and vaccines using a unique plant viral gene expression system that utilizes technology that originated at UC Riverside. Before the company closed in 2005, LSBC had garnered an international reputation as an innovator in biomanufacturing in plants and produced multi-kilogram quantities of therapeutic proteins and vaccine candidates. It had conducted successful human clinical trials, producing patient-specific vaccines as a therapeutic treatment for non-Hodgkin’s lymphoma cancer patients.

Grill has published over 25 peer-viewed scientific papers and is an inventor on more than 30 issued U.S. and world patents.

Media Contact

Tel: (951) 827-7847
Twitter: bettyemiller

Additional Contacts

Larry Grill

Mark Manalang

Archived under: Health, Politics/Society, Science/Technology, , , , , , , , , ,

Top of Page